Klaus Heese

Dr. Klaus Heese

Graduate School of Biomedical Science&Engineering, Hanyang University, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2000 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
CHChristoph Hock
Christoph Hock
Klaus HeeseKlaus Heese
Klaus Heese
CHChristine Hulette
Christine Hulette
CRCarlyn Rosenberg
Carlyn Rosenberg
UOUwe Otten
Uwe Otten
NERVE GROWTH factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4/5 (NT-4/5) are members of the neurotrophin gene family that support the survival, differentiation, maintenance, and repair of vertebrate neurons.1 Nerve growth factor supports the cholinergic neurons of the basal forebrain system.2 Brain-derived neurotrophic factor supports cholinergic, dopaminergic, 5-hydroxytryptamine, and neuropeptides containing neurons.3- 6 Neurotrophin 3 was shown to prevent the death of adult central noradrenergic neurons in vivo.7 Neuronal loss in Alzheimer disease (AD) includes the cholinergic neurons of the basal forebrain system, as well as neurons of the noradrenergic and serotonergic system.8 Previous reports demonstrated increased levels of NGF in cortical and subcortical brain areas including the frontal and parietal cortices and the hippocampus.9- 11 These increases were attributed to both reduced uptake and retrograde transport of NGF to NGF-sensitive cell bodies, since expression and protein levels of the NGF high-affinity receptor trkA were reduced in target regions of basal forebrain cholinergic neurons, such as the cortical association areas.12- 15 In contrast, BDNF messenger RNA levels were reported to be decreased in hippocampal neurons16 and BDNF protein levels were reported to be decreased in the entorhinal cortex of patients with AD.17 These results pointed to an opposite involvement of NGF and BDNF, which are both associated with trophic support of cholinergic neurons of the basal forebrain system, in the neuropathology of AD. To further explore the differential involvement of neurotrophins in AD, we quantitated protein levels of NGF, BDNF, NT-3, and NT-4/5 in well-characterized, rapid-autopsy–derived AD postmortem hippocampus, frontal and parietal cortices, and cerebellum, and compared them with age-matched control tissue. In addition, to control for potential effects of alterations in tissue wet weight on neurotrophin concentrations, we calculated neurotrophin/NT-3 ratios.

1 February 1998 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
Klaus HeeseKlaus Heese
Klaus Heese
CHChristoph Hock
Christoph Hock
UOUwe Otten
Uwe Otten
Inflammatory processes involving reactive microglia, e.g., those associated with β‐amyloid containing neuritic and core plaques in Alzheimer's disease, appear to contribute to neuronal degeneration in the CNS. The fact that increased nerve growth factor (NGF) protein levels were found throughout brains of Alzheimer's disease patients led us to investigate neurotrophin synthesis in a human microglial cell line showing typical properties of human microglial cells, including expression of neurotrophins such as NGF, as well as the NGF receptor trkA and the low‐affinity neurotrophin receptor p75. We found that the cytokines interleukin‐1β and tumor necrosis factor‐α synergistically stimulate microglial NGF transcription and protein release. Moreover, exposure of microglial cells to complement factor C3a induces NGF expression. To assess the role of the transcription factor nuclear factor‐κB (NF‐κB) in inflammatory mediator‐induced microglial NGF expression, the effect of the NF‐κB inhibitor pyrrolidine dithiocarbamate (PDTC) was analyzed. In the presence of PDTC, a dose‐dependent inhibition of cytokine‐activated NGF expression occurred. In contrast, the C3a‐dependent stimulation of NGF synthesis was not influenced by PDTC. In addition, microglial neurotoxicity‐mediating β‐amyloid peptides Aβ(1–40) and Aβ(1–42) failed to alter NGF synthesis, whereas Aβ(25–35) specifically induced NF‐κB‐dependent microglial NGF expression. In conclusion, inflammatory signals (cytokines and complement factors), as well as Aβ(25–35), are potent stimulators of human microglial NGF synthesis involving NF‐κB‐dependent and ‐independent mechanisms. Microglial secretion of neurotrophins appears to be involved in early processes of neuronal regeneration.

9 December 2014 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
TMTamilvendan Manavalan
Tamilvendan Manavalan
AMArulmani Manavalan
Arulmani Manavalan
Klaus HeeseKlaus Heese
Klaus Heese

1 February 2009 in Current Neurovascular Research
Verified
Journal Article
Closed access
PDF file
OIOmedul Islam
Omedul Islam
TLTze X. Loo
Tze X. Loo
Klaus HeeseKlaus Heese
Klaus Heese
Neurospheres can be generated from the mouse fetal forebrain by exposing multipotent neural stem cells (NSCs) to epidermal growth factor (EGF). In the presence of EGF, NSCs can proliferate continuously while retaining the potential to differentiate into neurons, astrocytes and oligodendrocytes. We examined the expression pattern of the neurotrophin (NT) receptors tropomysin-related kinase (TRK)-A, TRK-B, TRK-C and p75 neurotrophin receptor (p75NTR) in NSCs and the corresponding lineage cells. Furthermore, we analyzed the action of the NT Brain-Derived Neurotrophic Factor (BDNF) on NSCs behavior. The effects of BDNF on NSC proliferation and differentiation were examined together with the signaling pathways by which BDNF receptors transduce signaling effects. We found that all the known NT receptors, including the truncated isoforms of TRK-B (t-TRK-B) and TRK-C (t-TRK-C), were expressed by Nestin-positive cells within the neurosphere. Proliferation was enhanced in Nestin-positive and BrdU-positive cells in the presence of BDNF. In particular, we show that t-TRK-B was abundantly expressed in NSCs and the corresponding differentiated glia cells while full length TRK-B (fl-TRK-B) was expressed in fully differentiated post-mitotic neurons such as the neuronal cells of the newborn mouse cortex, suggesting that BDNF may exert its proliferative effects on NSCs through the t-TRK-B receptor. Finally, we analyzed the cell fates of NSCs differentiated with BDNF in the absence of EGF and we demonstrate that BDNF stimulated the formation of differentiated cell types in different proportions through the MAP kinase, AKT and STAT-3 signaling pathways. Thus, the in-vivo regulation of neurogenesis may be mediated by the summation of signals from the BDNF receptors, in particular the t-TRK-B receptor, regulating physiological fates as diverse as normal neural replacement, excessive neural loss, or tumor development.

1 January 2009 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
OIOmedul Islam
Omedul Islam
XGXiandi Gong
Xiandi Gong
SRStefan Rose-John
Stefan Rose-John
Klaus HeeseKlaus Heese
Klaus Heese
Besides its wide range of action as a proinflammatory cytokine in the immune system, interleukin-6 (IL-6) has also attracted much attention due to its influence on the nervous system. In the present study we show that the designer fusion protein H-IL-6, consisting of IL-6 and its specific receptor IL-6R-α, but not IL-6 alone, mediates both neuro- as well as gliogenesis. Using immunocytochemistry, Western blot, and patch-clamp recording, we demonstrate that H-IL-6 induces the differentiation of neural stem cells (NSCs) specifically into glutamate-responsive neurons and two morphological distinctive astroglia cell types. H-IL-6–activated neurogenesis seems to be induced by the MAPK/CREB (mitogen-activated protein kinase/cAMP response element-binding protein) cascade, whereas gliogenesis is mediated via the STAT-3 (signal transducers and activators of transcription protein-3) signaling pathway. Our finding that IL-6 mediates both processes depending on its specific soluble receptor sIL-6R-α has implications for the potential treatment of neurodegenerative diseases.

21 April 1999 in Glia
Verified
Journal Article
Closed access
PMPia März
Pia März
Klaus HeeseKlaus Heese
Klaus Heese
BDBeatrice Dimitriades‐Schmutz
Beatrice Dimitriades‐Schmutz
SRStefan Rose-John
Stefan Rose-John
UOUwe Otten
Uwe Otten